9 Geographic Atrophy Clinical Trials in Portland, OR (2026)

Q: How do I join a clinical trial in Portland?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you.

Recruiting Geographic Atrophy Studies in Portland

NCT07700979Recruiting

Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

The goal of this randomized, double-blind, multi-regional phase 3 study of cadonilimab combined with chemotherapy versus chemotherapy in combination with or without nivolumab for the first-line treatm...

Portland, ORPHASE3900 participantsAkeso

View Study Details

NCT06731478Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

This clinical trial is designed to assess the efficacy and safety of the triplet combination of trastuzumab deruxtecan (ENHERTU, T-DXd, DS-8201a) plus a fluoropyrimidine plus pembrolizumab versus stan...

Portland, ORPHASE3726 participantsDaiichi Sankyo

View Study Details

NCT06930625Recruiting

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind per...

Portland, ORPHASE3119 participantsDebiopharm International SA

View Study Details

NCT05957367Recruiting

A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies

This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master pro...

Portland, ORPHASE194 participantsDeciphera Pharmaceuticals, LLC

View Study Details

NCT06805825Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit....

Portland, ORPHASE167 participantsNovelty Nobility, Inc.

View Study Details

NCT06942572Recruiting

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

This Phase 1/2 study will evaluate the safety, tolerability, and preliminary efficacy of subretinal SB-007 administration to determine dose selection in subjects with Stargardt's Type 1 (STGD1). This...

Portland, ORPHASE157 participantsSplice Bio

View Study Details

NCT06560307Recruiting

Study of Enhanced Programming Stimulation with the Enterra® Therapy System

The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, a...

Portland, ORNA50 participantsEnterra Medical, Inc.

View Study Details

NCT06467344Recruiting

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for...

Portland, ORPHASE115 participantsAscidian Therapeutics, Inc

View Study Details

NCT07783412Recruiting

Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum

This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition th...

Portland, ORPHASE212 participantsOregon Health and Science University

View Study Details

About Geographic Atrophy Clinical Trials in Portland

Geographic atrophy is the advanced form of dry age-related macular degeneration, involving progressive loss of retinal cells. It leads to enlarging blind spots in central vision. Recently approved complement inhibitor therapies can slow progression.

There are currently 9 geographic atrophy clinical trials recruiting participants in Portland, OR. These studies are seeking a combined 2,040 participants. Research is being sponsored by Akeso, Daiichi Sankyo, Debiopharm International SA and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Geographic Atrophy Clinical Trials in Portland — FAQ

Are there geographic atrophy clinical trials in Portland?

Yes, there are 9 geographic atrophy clinical trials currently recruiting in Portland, OR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Portland?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Portland research site will contact you about next steps.

Are clinical trials in Portland free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Portland studies also compensate for your time and travel.

What geographic atrophy treatments are being tested?

The 9 active trials in Portland are testing new therapies including novel drugs, biologics, and treatment approaches for geographic atrophy.

Data updated October 19, 2026 from ClinicalTrials.gov